Connect
MJA
MJA

Overdiagnosis of screen‐detected breast cancer

Vivienne Milch, Sanchia Aranda, Karen Canfell, Megan Varlow, David M Roder, David Currow, Cleola Anderiesz and Dorothy Keefe
Med J Aust 2021; 214 (10): . || doi: 10.5694/mja2.51045
Published online: 17 May 2021

Screen‐detected breast cancer overdiagnosis occurs, but each woman has been diagnosed with cancer that cannot be ignored

There are an increasing number of publications estimating the extent of cancer overdiagnosis, which for breast cancer is in the context of population cancer screening programs.1 Researchers investigating overdiagnosis point to a range of related harms, but it is important to view these in the context of screening benefits, such as reductions in risk of breast cancer death.2 Care needs to be taken not to conflate formal screening programs with informal or opportunistic approaches to early detection, such as prostate‐specific antigen (PSA) testing in prostate cancer. This article focuses on the risk of overdiagnosis in the context of population‐based breast screening programs, given that overdiagnosis is often at the heart of calls to cease mammographic breast cancer screening.3,4 Despite the emphasis often given to breast cancer screening in discussions of overdiagnosis, the concept should not be regarded as only applying to breast cancer screening, or to cancer screening more generally, but as an outcome that could apply, to varying degrees, to a wider range of screening and diagnostic practices.

  • Vivienne Milch1
  • Sanchia Aranda2
  • Karen Canfell3
  • Megan Varlow4
  • David M Roder5
  • David Currow6
  • Cleola Anderiesz1
  • Dorothy Keefe1

  • 1 Cancer Australia, Sydney, NSW
  • 2 University of Melbourne, VIC
  • 3 Cancer Council NSW, Sydney, NSW
  • 4 Cancer Council Australia, Sydney, NSW
  • 5 Cancer Research Institute, University of South Australia, Adelaide, SA
  • 6 Cancer Institute NSW, Sydney, NSW


Competing interests:

Karen Canfell is the co‐principal investigator of an unrelated investigator‐initiated trial of cervical screening in Australia (Compass; ACTRN12613001207707 and NCT02328872), which is conducted and funded by the VCS Foundation — a government‐funded health promotion charity. The VCS Foundation received equipment and a funding contribution from Roche Molecular Systems and Ventana USA, but neither Karen Canfell nor her institution receives direct funding from industry for this trial or any other project. Dorothy Keefe is a consultant for Entrinsic Bioscience.

Author

remove_circle_outline Delete Author
add_circle_outline Add Author

Comment
Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Online responses are no longer available. Please refer to our instructions for authors page for more information.